<DOC>
	<DOCNO>NCT03046589</DOCNO>
	<brief_summary>Primary Objectives : 1 . To determine safety tolerability single multiple oral dos DP13 healthy male subject 2 . To assess pharmacodynamics single multiple ascend oral dos well dose regimen DP13 suppression serum aldosterone healthy male subject Secondary Objectives : 1 . To determine single multiple oral dose pharmacokinetics DP13 healthy male subject 2 . To determine dose-dependent pharmacodynamic selectivity DP13 healthy male subject</brief_summary>
	<brief_title>DP13 SAD &amp; MAD Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>1 . BMI 18.0 30.0 kg/m2 , inclusive 2. body weight 60 95 kg , inclusive 3. good health determine medical history , physical examination , vital sign assessment , 12lead ECG , clinical laboratory evaluation 4. normal stress response 5. sodium value within normal laboratory reference range 6. potassium value within normal laboratory reference range 7. write informed consent 1. unwilling consent whose partner unwilling consent use barrier method contraception 2. blood donation within 3 month prior screen plasma donation within 7 day prior screen platelet donation within 6 week prior screen 3. consumption 28 unit alcohol per week significant history alcoholism drug/chemical abuse within last 12 month prior screen 4. use tobacco nicotinecontaining product within 3 month 5. use follow within 14 day first dose : nonprescribed systemic topical medication ; herbal remedy ; vitamin supplement ; mineral supplement 6. receipt medication , include St John 's Wort , know chronically alter drug absorption elimination process 7. receipt intent receive : prescribed systemic topical medication within 14 day first dose administration 8. abnormality heart rate , blood pressure , temperature respiration rate screen prior first dose opinion investigator increase risk participate study 9. positive urine drug abuse screen 10. abnormality 12lead ECG screen prior first dose opinion investigator increase risk participate study 11. medical history clinically significant ECG abnormality family history prolong QTinterval syndrome 12. participation another clinical study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>